Wall Street brokerages expect that AxoGen, Inc. (NASDAQ:AXGN) will report earnings per share (EPS) of ($0.09) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for AxoGen’s earnings. The lowest EPS estimate is ($0.11) and the highest is ($0.07). AxoGen reported earnings per share of ($0.10) in the same quarter last year, which indicates a positive year over year growth rate of 10%. The company is expected to announce its next earnings results after the market closes on Wednesday, February 28th.
According to Zacks, analysts expect that AxoGen will report full-year earnings of ($0.32) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.31). For the next fiscal year, analysts expect that the business will post earnings of ($0.26) per share, with EPS estimates ranging from ($0.32) to ($0.20). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for AxoGen.
A number of equities analysts have recently commented on AXGN shares. Jefferies Group started coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 target price on the stock. Cantor Fitzgerald set a $37.00 target price on shares of AxoGen and gave the company a “buy” rating in a research note on Monday, January 8th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Leerink Swann raised their target price on shares of AxoGen from $23.00 to $26.00 and gave the company an “outperform” rating in a research note on Thursday, November 2nd. Finally, Wedbush reissued a “buy” rating and issued a $27.00 target price (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $29.33.
Institutional investors have recently added to or reduced their stakes in the stock. Valeo Financial Advisors LLC purchased a new stake in AxoGen during the 3rd quarter worth $244,000. Nationwide Fund Advisors increased its stake in AxoGen by 5.5% during the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 774 shares during the period. OxFORD Asset Management LLP purchased a new stake in AxoGen during the 3rd quarter worth $270,000. Teacher Retirement System of Texas purchased a new stake in AxoGen during the 4th quarter worth $271,000. Finally, Susquehanna International Group LLP increased its stake in AxoGen by 247.1% during the 2nd quarter. Susquehanna International Group LLP now owns 16,619 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 27,919 shares during the period. 65.94% of the stock is currently owned by hedge funds and other institutional investors.
Shares of AxoGen (NASDAQ AXGN) traded up $0.50 during mid-day trading on Wednesday, hitting $24.90. 414,682 shares of the stock were exchanged, compared to its average volume of 225,187. AxoGen has a fifty-two week low of $9.55 and a fifty-two week high of $31.70. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55. The stock has a market cap of $831.89, a P/E ratio of -62.25 and a beta of 0.12.
ILLEGAL ACTIVITY NOTICE: “-$0.09 Earnings Per Share Expected for AxoGen, Inc. (AXGN) This Quarter” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://sportsperspectives.com/2018/02/10/0-09-earnings-per-share-expected-for-axogen-inc-axgn-this-quarter.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.